查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1489375

2030 年臨床試驗影像市場預測：按產品、影像方式、應用、最終用戶和地區進行的全球分析

Clinical Trial Imaging Market Forecasts to 2030 - Global Analysis By Product (Software and Services), Imaging Modality, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球臨床試驗影像市場規模為 23.5 億美元，預計在預測期內複合年成長率為 8.6%，到 ​​2030 年將達到 45.2 億美元。

臨床試驗影像包括各種影像技術，用於評估臨床試驗中藥物、醫療設備和介入措施的安全性和有效性。這些影像對於評估疾病進展、治療效果和潛在副作用至關重要。透過提供詳細的解剖和功能訊息，診斷影像在確定臨床試驗的成功、幫助決策流程和推進醫學研究方面發揮關鍵作用。

根據ClinicalTrialsarena.com統計，2017年至2022年間，亞太地區（APAC）臨床試驗將出現約10%的顯著成長率，超過美國、歐洲和RoW等其他主要地區的成長率。

全球臨床試驗數量不斷增加

對藥物開發和個人化醫療的日益關注增加了對準確可靠的影像技術來評估治療的有效性和安全性的需求。臨床試驗利用 MRI、CT、PET 和超音波等影像方式進行病患分層、治療監測和終點評估。隨著製藥和生物技術公司尋求先進的診斷影像解決方案來支持其研究活動，臨床試驗中診斷影像需求的激增正在推動市場成長。

解釋上的變化

臨床試驗影像中的解釋變異性是由於設備、通訊協定和讀者專業知識的差異導致影像解釋不一致造成的。儘管努力標準化通訊協定並培訓讀者，但變異性仍然存在並影響資料可靠性和測試結果。這會降低人們對影像資料品質的信心、增加試驗持續時間以及增加與重複讀數和結果爭議相關的成本，從而阻礙市場成長。

轉向個人化醫療

臨床試驗影像在患者分層、治療監測和治療效果評估中發揮重要作用，滿足個人化醫療的目標。透過識別特定的生物標記，影像技術有助於選擇合適的患者進行臨床試驗、最佳化治療方法和評估治療效果。個人化醫療對診斷影像的日益依賴正在推動臨床試驗影像市場的成長。

實施成本高

臨床試驗影像的高實施成本是由於昂貴的設備、基礎設施需求和熟練的人員要求所造成的。這些成本構成了巨大的障礙，特別是對於中小企業 (SME) 和學術機構而言，限制了他們將影像納入臨床試驗的能力。這一限制限制了成像技術的採用並限制了以成像為終點進行的臨床試驗的範圍，從而阻礙了市場成長。

COVID-19 的影響

COVID-19 大流行對臨床試驗影像市場產生了重大影響。雖然疫情最初由於關閉和旅行限制而擾亂了臨床試驗活動，但它也凸顯了遠端監控和分散測試的重要性。虛擬和混合測試模型的快速採用增加了對支援遠端資料收集和分析的成像解決方案的需求。此外，對感染疾病研究和疫苗開發的關注進一步刺激了新冠臨床試驗對影像技術的需求，重塑了市場格局。

預計 X 光部分在預測期內將是最大的

X光產業預計將出現良好的成長。 X 光顯像模式由於其多功能性和廣泛可用性而對於臨床試驗成像至關重要。 X 光可非侵入性地顯示解剖結構，並可偵測骨骼異常、腫瘤和其他病灶。快速成像、相對較低的成本和完善的方案使其適合大規模臨床試驗。此外，數位放射成像和雙能量 X光吸收測定法等進步增強了其功能，並促進了其在不同治療領域的採用。

預計神經系統測試產業在預測期內將經歷最高的複合年成長率。

神經病學臨床試驗領域預計在預測期內將出現最高的複合年成長率。神經病學臨床試驗中的臨床試驗影像提供了一種評估大腦結構和功能變化的非侵入性方法，這對於開發阿茲海默症、帕金森氏症和多發性硬化症等神經系統疾病的治療方法至關重要。隨著神經系統疾病盛行率的增加和需要更有效的治療方法，神經系統臨床臨床實驗的應用在簡化臨床實驗、早期發現疾病和促進新治療方法。

佔比最大的地區：

預計亞太地區在預測期內將佔據最大的市場佔有率。醫療保健基礎設施投資的增加、臨床試驗活動的增加以及患者數量的增加正在促進該地區的市場擴張。亞太地區的成本優勢正在吸引製藥和生物技術公司在該地區進行臨床試驗。此外，支持性法律規範和影像技術的進步進一步刺激了市場成長。由於對精準醫療的重視以及對創新治療方法的需求不斷成長，亞太地區臨床試驗影像市場有望實現顯著成長和機會。

複合年成長率最高的地區：

由於其成熟度、技術先進性和堅實的基礎設施，預計北美在預測期內將呈現最高的複合年成長率。該地區擁有完善的醫療保健體系和 FDA 等強大的法規結構，吸引了大量的全球臨床試驗。大型製藥企業的存在以及強大的研發活動也支持了市場成長。北美還擁有技術熟練的勞動力、尖端成像技術和大量患者群體的優勢。這些因素共同促成了該地區的市場主導地位。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球臨床試驗影像市場：按產品

  • 軟體
    • 影像分析軟體
    • 電子資料擷取(EDC) 軟體
    • 影像資料管理軟體
    • 3D影像軟體
  • 服務
    • 影像核心實驗室服務
    • 現場影像服務
    • 影像診斷諮詢服務
    • 監理合規服務

第6章 世界各地的臨床試驗影像地點：依影像方式分類

  • 磁振造影(MRI)
  • 電腦斷層掃描 (CT)
  • 正子斷層掃描 (PET)
  • 單光子發射電腦斷層掃描 (SPECT)
  • 超音波
  • X光
  • 其他成像方式

第7章全球臨床試驗影像市場：依應用分類

  • 腫瘤學測試
  • 神經學檢查
  • 心臟病學檢查
  • 風濕病檢查
  • 內分泌檢查
  • 其他用途

第8章全球臨床試驗影像市場：依最終使用者分類

  • 合約研究組織（CRO）
  • 生技公司
  • 學術研究所
  • 其他最終用戶

第9章全球臨床試驗影像市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司概況

  • Biomedical Systems
  • Cardinal Health
  • ICON plc
  • IXICO plc
  • BioTelemetry Inc.
  • Covance Inc.
  • Parexel International Corporation
  • Clario Medical Imaging Inc.
  • Intrinsic Imaging LLC
  • Radiant Sage LLC
  • ERT（eResearchTechnology）
  • Navitas Life Sciences
  • Resonance Health
  • ProScan Imaging
  • Medpace
Product Code: SMRC26161

According to Stratistics MRC, the Global Clinical Trial Imaging Market is accounted for $2.35 billion in 2023 and is expected to reach $4.52 billion by 2030 growing at a CAGR of 8.6% during the forecast period. Clinical Trial Imaging involves the use of various imaging techniques to assess the safety and efficacy of drugs, medical devices, or interventions in clinical trials. These images are crucial for evaluating disease progression, treatment response, and potential side effects. By providing detailed anatomical and functional information, imaging plays a vital role in determining the success of clinical trials, aiding in decision-making processes, and advancing medical research.

According to Clinicaltrialsarena.com, in the period between 2017 and 2022, the Asia-Pacific (APAC) region experienced a remarkable growth rate of around 10% in clinical trials, surpassing the growth rate of other major regions such as the US, Europe, and RoW.

Market Dynamics:

Driver:

Mounting number of clinical trials globally

With an increasing focus on drug development and personalized medicine, there's a growing demand for accurate and reliable imaging technologies to assess treatment efficacy and safety. Clinical trials utilize imaging modalities such as MRI, CT, PET, and ultrasound for patient stratification, treatment monitoring, and endpoint assessment. This surge in demand for imaging in clinical trials boosts market growth as pharmaceutical and biotechnology companies seek advanced imaging solutions to support their research endeavours.

Restraint:

Interpretation variabilities

Interpretation variabilities in clinical trial imaging stem from differences in equipment, protocols, and reader expertise, leading to inconsistent image interpretations. Despite efforts to standardize protocols and train readers, variability persists, impacting data reliability and study outcomes. This hampers market growth by eroding confidence in imaging data quality, prolonging study timelines, and increasing costs associated with repeated readings or disputes over results.

Opportunity:

Shift towards personalized medicine

Clinical trial imaging plays a crucial role in patient stratification, treatment monitoring, and assessing treatment response, aligning with the objectives of personalized medicine. By enabling the identification of specific biomarkers, imaging technologies facilitate the selection of suitable patients for clinical trials, optimization of treatment regimens, and evaluation of therapeutic efficacy. This increased reliance on imaging in personalized medicine fuels the growth of the Clinical Trial Imaging market.

Threat:

High implementation costs

High implementation costs in clinical trial imaging stem from expensive equipment, infrastructure needs, and skilled personnel requirements. These costs pose a significant barrier, particularly for small and medium-sized enterprises (SMEs) and academic institutions, limiting their ability to incorporate imaging into clinical trials. This limitation hampers market growth by constraining the adoption of imaging techniques and restricting the scope of clinical trials conducted with imaging endpoints.

Covid-19 Impact

The covid-19 pandemic has significantly impacted the clinical trial imaging market. While the pandemic initially led to disruptions in clinical trial activities due to lockdowns and travel restrictions, it also highlighted the importance of remote monitoring and decentralized trials, where imaging plays a critical role. The adoption of virtual and hybrid trial models surged, driving demand for imaging solutions that support remote data collection and analysis. Additionally, the focus on infectious disease research and vaccine development further stimulated demand for imaging technologies in covid clinical trials, reshaping the market landscape.

The X-ray segment is expected to be the largest during the forecast period

The X-ray segment is estimated to have a lucrative growth. X-ray imaging modality is integral to Clinical Trial Imaging due to its versatility and widespread availability. It offers non-invasive visualization of anatomical structures and can detect skeletal abnormalities, tumours, and other pathologies. Its rapid acquisition, relatively low cost, and established protocols make it suitable for large-scale trials. Additionally, advancements like digital radiography and dual-energy X-ray absorptiometry enhance its capabilities, driving its adoption in diverse therapeutic areas.

The neurology trials segment is expected to have the highest CAGR during the forecast period

The neurology trials segment is anticipated to witness the highest CAGR growth during the forecast period. Clinical Trial Imaging in Neurology Trials offers non-invasive methods to assess structural and functional changes in the brain, crucial for developing treatments for neurological disorders like Alzheimer's, Parkinson's, and multiple sclerosis. With the rising prevalence of neurological disorders and the demand for more effective therapies, it plays a vital role in enhancing trial efficiency, enabling early disease detection, and advancing the development of novel treatments, driving its application in neurology trials.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period. The region's increasing investment in healthcare infrastructure, rising clinical trial activity, and a large patient pool contribute to market expansion. APAC offers cost advantages, attracting pharmaceutical and biotechnology companies to conduct clinical trials in the region. Additionally, supportive regulatory frameworks and advancements in imaging technologies further stimulate market growth. With a growing emphasis on precision medicine and the need for innovative therapies, the APAC Clinical Trial Imaging market is poised for significant development and opportunities.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to its maturity, technological advancements, and robust infrastructure. With a well-established healthcare system and strong regulatory frameworks like the FDA, the region attracts a significant share of global clinical trials. The presence of leading pharmaceutical and biotechnology companies, coupled with a high level of research and development activities, drives market growth. Additionally, North America benefits from a skilled workforce, access to cutting-edge imaging technologies, and a large patient population. These factors collectively contribute to the region's dominance in the market.

Key players in the market

Some of the key players profiled in the Clinical Trial Imaging Market include Biomedical Systems, Cardinal Health, ICON plc, IXICO plc, BioTelemetry Inc., Covance Inc., Parexel International Corporation, Clario Medical Imaging Inc., Intrinsic Imaging LLC, Radiant Sage LLC, ERT (eResearchTechnology), Navitas Life Sciences, Resonance Health, ProScan Imaging, Medpace.

Key Developments:

In May 2023, Cleerly has partnered with ProScan Imaging to provide personalized solutions for cardiac health, which involve analyzing and devising treatment strategies for cardiovascular issues.

In March 2023, ICON PLC (Ireland) announced a strategic partnership with LEO Pharma (Denmark) to scale clinical trial execution that is patient-centric and cost effective, and which will support the company's overall ambition of building one of the most effective and efficient clinical portfolio execution organisations in the industry.

In March 2023, Clario (US), announced the launch of a cutting-edge cloud-based image viewer tool for sponsors and contract research organizations to view images related to their clinical trials.

Products Covered:

  • Software
  • Services

Imaging Modalities Covered:

  • Magnetic Resonance Imaging (MRI)
  • Computed Tomography (CT)
  • Positron Emission Tomography (PET)
  • Single-Photon Emission Computed Tomography (SPECT)
  • Ultrasound
  • X-Ray
  • Other Imaging Modalities

Applications Covered:

  • Oncology Trials
  • Neurology Trials
  • Cardiology Trials
  • Rheumatology Trials
  • Endocrinology Trials
  • Other Applications

End Users Covered:

  • Contract Research Organizations (CROs)
  • Biotechnology Companies
  • Academic and Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Clinical Trial Imaging Market, By Product

  • 5.1 Introduction
  • 5.2 Software
    • 5.2.1 Image Analysis Software
    • 5.2.2 Electronic Data Capture (EDC) Software
    • 5.2.3 Imaging Data Management Software
    • 5.2.4 3D Imaging Software
  • 5.3 Services
    • 5.3.1 Imaging Core Lab Services
    • 5.3.2 Site Imaging Services
    • 5.3.3 Imaging Consultation Services
    • 5.3.4 Regulatory Compliance Services

6 Global Clinical Trial Imaging Market, By Imaging Modality

  • 6.1 Introduction
  • 6.2 Magnetic Resonance Imaging (MRI)
  • 6.3 Computed Tomography (CT)
  • 6.4 Positron Emission Tomography (PET)
  • 6.5 Single-Photon Emission Computed Tomography (SPECT)
  • 6.6 Ultrasound
  • 6.7 X-Ray
  • 6.8 Other Imaging Modalities

7 Global Clinical Trial Imaging Market, By Application

  • 7.1 Introduction
  • 7.2 Oncology Trials
  • 7.3 Neurology Trials
  • 7.4 Cardiology Trials
  • 7.5 Rheumatology Trials
  • 7.6 Endocrinology Trials
  • 7.7 Other Applications

8 Global Clinical Trial Imaging Market, By End User

  • 8.1 Introduction
  • 8.2 Contract Research Organizations (CROs)
  • 8.3 Biotechnology Companies
  • 8.4 Academic and Research Institutes
  • 8.5 Other End Users

9 Global Clinical Trial Imaging Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Biomedical Systems
  • 11.2 Cardinal Health
  • 11.3 ICON plc
  • 11.4 IXICO plc
  • 11.5 BioTelemetry Inc.
  • 11.6 Covance Inc.
  • 11.7 Parexel International Corporation
  • 11.8 Clario Medical Imaging Inc.
  • 11.9 Intrinsic Imaging LLC
  • 11.10 Radiant Sage LLC
  • 11.11 ERT (eResearchTechnology)
  • 11.12 Navitas Life Sciences
  • 11.13 Resonance Health
  • 11.14 ProScan Imaging
  • 11.15 Medpace

List of Tables

  • Table 1 Global Clinical Trial Imaging Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Clinical Trial Imaging Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Clinical Trial Imaging Market Outlook, By Software (2021-2030) ($MN)
  • Table 4 Global Clinical Trial Imaging Market Outlook, By Image Analysis Software (2021-2030) ($MN)
  • Table 5 Global Clinical Trial Imaging Market Outlook, By Electronic Data Capture (EDC) Software (2021-2030) ($MN)
  • Table 6 Global Clinical Trial Imaging Market Outlook, By Imaging Data Management Software (2021-2030) ($MN)
  • Table 7 Global Clinical Trial Imaging Market Outlook, By 3D Imaging Software (2021-2030) ($MN)
  • Table 8 Global Clinical Trial Imaging Market Outlook, By Services (2021-2030) ($MN)
  • Table 9 Global Clinical Trial Imaging Market Outlook, By Imaging Core Lab Services (2021-2030) ($MN)
  • Table 10 Global Clinical Trial Imaging Market Outlook, By Site Imaging Services (2021-2030) ($MN)
  • Table 11 Global Clinical Trial Imaging Market Outlook, By Imaging Consultation Services (2021-2030) ($MN)
  • Table 12 Global Clinical Trial Imaging Market Outlook, By Regulatory Compliance Services (2021-2030) ($MN)
  • Table 13 Global Clinical Trial Imaging Market Outlook, By Imaging Modality (2021-2030) ($MN)
  • Table 14 Global Clinical Trial Imaging Market Outlook, By Magnetic Resonance Imaging (MRI) (2021-2030) ($MN)
  • Table 15 Global Clinical Trial Imaging Market Outlook, By Computed Tomography (CT) (2021-2030) ($MN)
  • Table 16 Global Clinical Trial Imaging Market Outlook, By Positron Emission Tomography (PET) (2021-2030) ($MN)
  • Table 17 Global Clinical Trial Imaging Market Outlook, By Single-Photon Emission Computed Tomography (SPECT) (2021-2030) ($MN)
  • Table 18 Global Clinical Trial Imaging Market Outlook, By Ultrasound (2021-2030) ($MN)
  • Table 19 Global Clinical Trial Imaging Market Outlook, By X-Ray (2021-2030) ($MN)
  • Table 20 Global Clinical Trial Imaging Market Outlook, By Other Imaging Modalities (2021-2030) ($MN)
  • Table 21 Global Clinical Trial Imaging Market Outlook, By Application (2021-2030) ($MN)
  • Table 22 Global Clinical Trial Imaging Market Outlook, By Oncology Trials (2021-2030) ($MN)
  • Table 23 Global Clinical Trial Imaging Market Outlook, By Neurology Trials (2021-2030) ($MN)
  • Table 24 Global Clinical Trial Imaging Market Outlook, By Cardiology Trials (2021-2030) ($MN)
  • Table 25 Global Clinical Trial Imaging Market Outlook, By Rheumatology Trials (2021-2030) ($MN)
  • Table 26 Global Clinical Trial Imaging Market Outlook, By Endocrinology Trials (2021-2030) ($MN)
  • Table 27 Global Clinical Trial Imaging Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 28 Global Clinical Trial Imaging Market Outlook, By End User (2021-2030) ($MN)
  • Table 29 Global Clinical Trial Imaging Market Outlook, By Contract Research Organizations (CROs) (2021-2030) ($MN)
  • Table 30 Global Clinical Trial Imaging Market Outlook, By Biotechnology Companies (2021-2030) ($MN)
  • Table 31 Global Clinical Trial Imaging Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
  • Table 32 Global Clinical Trial Imaging Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.